| 1 |
35533600 | Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway. | 2022 Jul 12 |
2 |
| 2 |
34439125 | ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer. | 2021 Aug 5 |
1 |
| 3 |
34681618 | Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target. | 2021 Oct 11 |
1 |
| 4 |
31967357 | Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. | 2020 Apr |
4 |
| 5 |
32042320 | Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. | 2020 |
1 |
| 6 |
32054790 | Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. | 2020 Apr |
3 |
| 7 |
32205016 | A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. | 2020 May |
1 |
| 8 |
32371590 | Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor. | 2020 Jul |
1 |
| 9 |
31126320 | Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. | 2019 May 24 |
2 |
| 10 |
31228231 | Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. | 2019 Aug |
3 |
| 11 |
29220539 | Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. | 2018 Jun |
1 |
| 12 |
27046225 | Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. | 2016 |
1 |
| 13 |
25151012 | Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. | 2015 Jun |
2 |
| 14 |
26378044 | AR-v7 protein expression is regulated by protein kinase and phosphatase. | 2015 Oct 20 |
1 |